

MOUNTAINSIDE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (OTC: NHGI) today announced the engagement of Burt Martin Arnold Securities, Inc. ("BMA Securities") to provide advisory and investment banking services with respect to assisting and advising the company with a current capital raise of \$3,500,000.

BMA Securities is a FINRA member full service brokerage firm. BMA Securities offers a wide array of financial services, which include: market making, institutional trading, investment banking, advisory and consulting services.

National Stem Cell President Michael Cohen, stated: "We welcome BMA Securities to our team and look forward to a long working relationship with them. They are assisting us with our current funding and possibly future mergers and acquisitions the company is looking at in the future."

For more information on National Stem Cell Holding, Inc. please contact us at the company website: <http://www.nationalstemcell.com> or <http://www.pinksheets.com> .

About National Stem Cell Holding, Inc.

National Stem Cell Holding, Inc. is a hybrid biotechnology company focused on developing therapeutics based upon the use of human stem cells and their derivatives. The term 'hybrid' refers to both the business model as well its product line. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. Many of the currently incurable diseases associated with aging are caused by the degeneration of specific cell types in the body. These include but are not limited to: cancer, heart disease, diabetes, neurodegenerative diseases and auto immune conditions. In addition to its work with stem cell therapeutics, the Company is leveraging its commercial infrastructure and product development capabilities of its wholly-owned subsidiaries The Sperm Bank of NY (tissue Bank and IVF laboratory) and National Stem Cell Blood Laboratories Inc (cord blood banking program), and its affiliate, Decouverte Cosmetique, Inc. (cosmetics). The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company's multi-faceted R&D program has demonstrated results with over 10 patent applications and multiple products ready to enter the market. The Company is headquartered in Mountainside, NJ and has facilities at multiple academic institutions.

"Safe Harbor Statement"

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact:

Michael Cohen

187 Mill Lane

Mountainside, NJ 07052

Phone: (212)792-6188

[ir@nationalstemcell.com](mailto:ir@nationalstemcell.com)